Vivani Medical is a clinical-stage, biopharmaceutical company developing a pipeline of miniature, ultra Long-acting, subdermal, drug implants with its proprietary NanoPortal™ technology.
Vivani’s lead assets, NPM-130 and NPM-133, are miniature, six-month, GLP-1 (semaglutide) implants under development for chronic weight management obesity and type 2 diabetes, respectively. NPM-130 and NPM-133 are designed to optimize GLP-1 therapy by addressing two main challenges in achieving the full potential benefits of this therapy, medication non-adherence and tolerability.